#healthcare #Israel #Ultrasound #Ramat Gan #Pulsenmore

Pulsenmore Secures $7.5 Million Funding for Expansion

Pulsenmore Ltd., recognized as a leader in home ultrasound innovation, has unveiled a significant financial move by entering into a private placement worth $7.5 million. This agreement, struck with a prominent institutional investor focused on healthcare, reflects Pulsenmore's strategic initiatives aimed at enhancing its market position, particularly in the U.S.

This private placement involves the sale of 1,562,500 ordinary shares, along with accompanying warrants, at a price of $4.80 each. This amount is not only expected to bolster the company financially but is also anticipated to play a crucial role in expanding its operational capabilities. The gross proceeds from this offering will predominantly support Pulsenmore's marketing and commercialization efforts, as well as providing vital working capital.

Elazar Sonnenschein, the Chief Executive Officer of Pulsenmore, remarked, "This financing supports our next phase of growth and is intended to enable us to further expand our commercial footprint, particularly in the U.S. market, increase market penetration, and execute on strategic initiatives designed to drive long-term growth. We remain focused on advancing our mission, strengthening our market position, and delivering sustainable value to all stakeholders."

This funding round underscores Pulsenmore's commitment to revolutionizing maternal health through accessible ultrasound technology, which allows remote consultations between mothers and healthcare providers. Their pioneering approach not only enhances prenatal care accessibility but also aims to improve the continuity of care for pregnant women.

The expected closing date for the offering is around June 26, 2026, pending the usual closing conditions. A.G.P./Alliance Global Partners is acting as the exclusive placement agent for this offering, ensuring a smooth transition to bolster Pulsenmore's financial foundation.

It’s noteworthy that this offer falls under the exemption provisions outlined in the Securities Act of 1933. Consequently, the securities sold in this private placement will not be initially registered under the Securities Act, emphasizing the selective nature of the offering to ensure compliance and legitimacy within the frameworks of state and federal securities laws.

In relation to these developments, Pulsenmore is set to file a registration statement with the U.S. Securities and Exchange Commission regarding the resale of ordinary shares and warrants involved in this transaction, highlighting their proactive stance in adhering to regulatory requirements.

As Pulsenmore continues to make strides in the medical technology landscape, this latest injection of capital presents promising opportunities for both growth and innovation in delivering quality prenatal care. With the increased focus on telemedicine and remote healthcare solutions, Pulsenmore's efforts may significantly alleviate barriers that many expectant mothers face when seeking essential medical guidance.

Potential investors and current stakeholders are encouraged to keep an eye on Pulsenmore’s developments as the company forges ahead, aiming to capitalize on this unique position within the healthcare industry, where the intersection of technology and maternal health can yield transformative benefits for many families.

For further details on the company's offerings and future initiatives, one can visit Pulsenmore’s official website at www.pulsenmore.com. This platform emphasizes their dedication to improving maternal health outcomes through technological advancements, and the new funding will significantly aid their mission to enhance healthcare accessibility.

As we move further into an era that increasingly values integrated healthcare technologies, Pulsenmore is poised to lead the way in providing innovative solutions that reliably connect healthcare providers with patients at home.